Jose L. Ochoa-Bayona, MD

BOARD CERTIFICATION:
          •  Hematology
          •  Medical Oncology

FELLOWSHIP:
          •  University of Texas Health Science Center, San Antonio - Bone Marrow Transplantation
          •  University of Texas Health Science Center, San Antonio - Medical Oncology/Hematology
          •  Universidad Autonoma de Nuevo Leon - Gastroenterology

RESIDENCY:
          •  University of Texas Health Science Center, San Antonio - Internal Medicine
          •  Universidad Autonoma de Nuevo Leon - Internal Medicine

MEDICAL SCHOOL:
          •  Universidad Autonoma de Nuevo Leon - Physician, Surgeon, Midwife

• Kharfan-Dabaja MA, Anasetti C, Fernandez HF, Perkins J, Ochoa-Bayona JL, Pidala J, Perez LE, Ayala E, Field T, Alsina M, Nishihori T, Locke F, Pinilla-Ibarz J, Tomblyn M. Phase II study of CD4+guided pentostatin lymphodepletion and pharmacokinetically-targeted busulfan as conditioning for hematopoietic cell allografting. Biol Blood Marrow Transplant. 2013 Apr. Pubmedid: 23632090.


• Nishihori T, Ochoa-Bayona JL, Kim J, Pidala J, Shain K, Baz R, Sullivan D, Jim HS, Anasetti C, Alsina M. Allogeneic hematopoietic cell transplantation for consolidation of VGPR or CR for newly diagnosed multiple myeloma. Bone Marrow Transplant. 2013 Apr. Pubmedid: 23542223.


• Pidala J, Kim J, Schell M, Lee SJ, Hillgruber R, Nye V, Ayala E, Alsina M, Betts B, Bookout R, Fernandez HF, Field T, Locke FL, Nishihori T, Ochoa JL, Perez L, Perkins J, Shapiro J, Tate C, Tomblyn M, Anasetti C. Race/ethnicity affects the probability of finding an HLA-A, -B, -C and -DRB1 allele-matched unrelated donor and likelihood of subsequent transplant utilization. Bone Marrow Transplant. 2013 Mar;48(3):346-350. Pubmedid: 22863723.


• Nishihori T, Alekshun TJ, Shain K, Sullivan DM, Baz R, Perez L, Pidala J, Kharfan-Dabaja MA, Ochoa-Bayona JL, Fernandez HF, Yarde DN, Oliveira V, Fulp W, Han G, Kim J, Chen DT, Raychaudhuri J, Dalton W, Anasetti C, Alsina M. Bortezomib salvage followed by a Phase I/II study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myeloma. Br J Haematol. 2012 Jun;157(5):553-563. Pubmedid: 22449149.


• Alay?n-Laguer D, Alsina M, Ochoa-Bayona JL, Ayala E. Melphalan Culprit or Confounder in Acute Encephalopathy during Autologous Hematopoietic Stem Cell Transplantation?. Case Rep Transplant. 2012;2012:942795. Pubmedid: 23259145. Pmcid: PMC3505956.


• Liu JJ, Zhang L, Ayala E, Field T, Ochoa-Bayona JL, Perez L, Bello CM, Chervenick PA, Bruno S, Cultrera JL, Baz RC, Kharfan-Dabaja MA, Raychaudhuri J, Sotomayor EM, Sokol L. Human immunodeficiency virus (HIV)-negative plasmablastic lymphoma: a single institutional experience and literature review. Leuk Res. 2011 Dec;35(12):1571-1577. Pubmedid: 21752466.


• Lebovic D, Zhang L, Alsina M, Nishihori T, Shain KH, Sullivan D, Ochoa-Bayona JL, Kharfan-Dabaja MA, Baz R. Clinical outcomes of patients with plasma cell leukemia in the era of novel therapies and hematopoietic stem cell transplantation strategies: a single-institution experience. Clin Lymphoma Myeloma Leuk. 2011 Dec;11(6):507-511. Pubmedid: 21813352.


• Pidala J, Tomblyn M, Nishihori T, Ayala E, Field T, Fernandez H, Perez L, Locke F, Alsina M, Ochoa JL, Perkins J, Tate C, Shapiro J, Conwell M, Bookout R, Anasetti C. ATG Prevents Severe Acute Graft-versus-Host Disease in Mismatched Unrelated Donor Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2011 Aug;17(8):1237-1244. Pubmedid: 21215811.


• Nishihori T, Fernandez HF, Coppola D, Ochoa-Bayona JL, Lancet JE, Komrokji RS, Kharfan-Dabaja MA. Hepatobiliary manifestations of acute myeloid leukemia. Leuk Res. 2011 Jun;35(6):e81-e83. Pubmedid: 21232795.


• Pidala J, Roman-Diaz J, Kim J, Nishihori T, Perkins J, Tate C, Ochoa-Bayona JL, Field T, Fernandez HF, Tomblyn M, Ayala E, Anasetti C, Kharfan-Dabaja MA. Targeted IV busulfan and fludarabine followed by post-allogeneic hematopoietic cell transplantation rituximab demonstrate encouraging activity in CD20+ lymphoid malignancies without increased risk of infectious complications. Int J Hematol. 2011 Feb;93(2):206-212. Pubmedid: 21246311.


• Nishihori T, Kharfan-Dabaja MA, Ochoa-Bayona JL, Bazarbachi A, Pasquini M, Alsina M. Role of reduced intensity conditioning in allogeneic hematopoietic cell transplantation for patients with multiple myeloma. Hematol Oncol Stem Cell Ther. 2011;4(1):1-9. Pubmedid: 21460601.


• Hoda D, Pidala J, Salgado-Vila N, Kim J, Perkins J, Bookout R, Field T, Perez L, Ayala E, Ochoa-Bayona JL, Raychaudhuri J, Alsina M, Greene J, Janssen W, Fernandez HF, Anasetti C, Kharfan-Dabaja MA. Sirolimus for treatment of steroid-refractory acute graft-versus-host disease. Bone Marrow Transplant. 2010 Aug;45(8):1347-1351. Pubmedid: 19966849.


• Perkins J, Field T, Kim J, Kharfan-Dabaja MA, Fernandez H, Ayala E, Perez L, Xu M, Alsina M, Ochoa L, Sullivan D, Janssen W, Anasetti C. A Randomized Phase II Trial Comparing Tacrolimus and Mycophenolate Mofetil to Tacrolimus and Methotrexate for Acute Graft-versus-Host Disease Prophylaxis. Biol Blood Marrow Transplant. 2010 Jul;16(7):937-947. Pubmedid: 20102746.


• Burzynski JA, Toro JJ, Patel RC, Lee S, Greene RE, Ochoa-Bayona JL, Frei CR, Freytes CO. Toxicity of a second autologous peripheral blood stem cell transplant in patients with relapsed or recurrent multiple myeloma. Leuk Lymphoma. 2009 Sep;50(9):1442-1447. Pubmedid: 19637091.


• Toro J, Morales M, Loberiza F, Ochoa-Bayona J, Freytes C. Patterns of use of vascular access devices in patients undergoing hematopoietic stem cell transplantation: results of an international survey. Support Care Cancer. 2007 Dec;15(12):1375-1383. Pubmedid: 17486374.


• McKibbin T, Burzynski J, Greene R, Ochoa-Bayona J, Tsai TW, Callander N, Freytes C. Paclitaxel and filgrastim for hematopoietic progenitor cell mobilization in patients with hematologic malignancies after failure of a prior mobilization regimen. Leuk Lymphoma. 2007 Dec;48(12):2360-2366. Pubmedid: 18067011.


• Arango J, Restrepo A, Schneider D, Callander N, Ochoa-Bayona J, RestrepoMI, Bradshaw P, Patterson J, Freytes C. Incidence of Clostridium difficile-associated diarrhea before and after autologous peripheral blood stem cell transplantation for lymphoma and multiple myeloma. Bone Marrow Transplant. 2006 Mar;37(5):517-521. Pubmedid: 16435018.


• Ricart A, Hammond L, Kuhn J, Takimoto C, Goetz A, Forouzesh B, Forero L, Ochoa-Bayona J, Berg K, Tolcher A, Rowinsky E. Phase I and pharmacokinetic study of sequences of the rebeccamycin analogue NSC 655649 and cisplatin in patients with advanced solid tumors. Clin Cancer Res. 2005 Dec;11(24 Pt 1):8728-8736. Pubmedid: 16361560.

Dr. Jose Ochoa-Bayona is a medical oncologist in the Blood and Marrow Transplant Department at Moffitt Cancer Center and an assistant professor in the Department of Oncologic Sciences and the Department of Internal Medicine at the University of South Florida.
Dr. Ochoa-Bayona’s research interest includes early phase clinical trials of autologous and allogeneic stem cell transplantation and post-transplant immunotherapy for multiple myeloma.
A graduate of Universidad Autonoma de Nuevo Leon Medical School in Mexico, Dr. Ochoa-Bayona served a residency in internal medicine and a fellowship in gastroenterology at the university-affiliated Dr. José E.  Gonzalez Medical Center.  He was chief resident during his residency.

Dr. Ochoa-Bayona pursued additional training at the University of Texas Health Science Center in San Antonio, where he completed a second internal medicine residency and fellowship programs in medical oncology/hematology and bone marrow transplantation.

Prior to joining Moffitt in 2007, he was an assistant professor of medicine in the hematology division and adult bone marrow transplant program at UT Health Science Center at San Antonio.  He was also a staff physician in the bone marrow transplant unit at the Audie L. Murphy Memorial Veterans Affairs Medical Center in San Antonio. 

Dr. Ochoa-Bayona has received two American Society of Clinical Oncology Merit Awards, an American Association for Cancer Research Scholar in Training Award and was named an AMGEN Oncology Fellow.  His research has been widely published in peer-reviewed publications.